Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Ethyl 4-[(4-methylpyridin-2-yl)amino]piperidine‑1‑carboxylate is a synthetic small molecule belonging to the class of _piperidinecarboxylic acids_, characterized by a piperidine ring substituted with an ethoxycarbonyl group and a _(4-methylpyridin‑2-yl)amino moiety_[1][3][5]. It has been studied as an experimental compound, notably for its inhibitory activity against nitric oxide synthase isoforms, particularly _inducible nitric oxide synthase (iNOS/NOS2)_, with reported IC50 values in the nanomolar range for iNOS and much weaker inhibition of _endothelial NOS (eNOS/NOS3)_[4][5]. There are no approved therapeutic indications or marketed products containing this compound. Its primary research interest lies in enzyme inhibition relevant to inflammation and related pathologies.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on ethyl 4-[(4-methylpyridin-2-yl)amino]piperidine-1-carboxylate.